78 related articles for article (PubMed ID: 21631182)
1. Toxicodynamic evaluation of a cisplatin-chondroitin sulfate complex using a perfused kidney and human proximal tubular cells.
Zhang JS; Kadowaki D; Nonoguchi H; Hirata S; Seo H; Imai T; Suenaga A; Giam Chuang VT; Otagiri M
Ren Fail; 2011; 33(6):609-14. PubMed ID: 21631182
[TBL] [Abstract][Full Text] [Related]
2. Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin.
Zhang JS; Imai T; Otagiri M
Arch Toxicol; 2000 Aug; 74(6):300-7. PubMed ID: 11005675
[TBL] [Abstract][Full Text] [Related]
3. Molecular-weight-dependent pharmacokinetics and cytotoxic properties of cisplatin complexes prepared with chondroitin sulfate A and C.
Zhang JS; Imai T; Suenaga A; Otagiri M
Int J Pharm; 2002 Jun; 240(1-2):23-31. PubMed ID: 12062498
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of p21 modifies the response of cortical proximal tubules to cisplatin in rats.
Zhou H; Fujigaki Y; Kato A; Miyaji T; Yasuda H; Tsuji T; Yamamoto T; Yonemura K; Hishida A
Am J Physiol Renal Physiol; 2006 Jul; 291(1):F225-35. PubMed ID: 16467127
[TBL] [Abstract][Full Text] [Related]
5. The cellular toxicity of two antitumoural agents derived from platinum, cisplatinum versus oxaliplatinum, on cultures of tubular proximal cells.
Legallicier B; Leclere C; Monteil C; Elkaz V; Morin JP; Fillastre JP
Drugs Exp Clin Res; 1996; 22(2):41-50. PubMed ID: 8879978
[TBL] [Abstract][Full Text] [Related]
6. Reversal of cisplatin-induced carnitine deficiency and energy starvation by propionyl-L-carnitine in rat kidney tissues.
Aleisa AM; Al-Majed AA; Al-Yahya AA; Al-Rejaie SS; Bakheet SA; Al-Shabanah OA; Sayed-Ahmed MM
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1252-9. PubMed ID: 17973863
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin nephrotoxicity and protection by silibinin.
Gaedeke J; Fels LM; Bokemeyer C; Mengs U; Stolte H; Lentzen H
Nephrol Dial Transplant; 1996 Jan; 11(1):55-62. PubMed ID: 8649653
[TBL] [Abstract][Full Text] [Related]
8. Spectroscopic studies of interactions of chondroitin sulfates with cisplatin.
Zhang JS; Anraku M; Kadowaki D; Imai T; Suenaga A; Odani A; Otagiri M
Carbohydr Res; 2011 Apr; 346(5):631-7. PubMed ID: 21324437
[TBL] [Abstract][Full Text] [Related]
9. Stability of a cisplatin-chondroitin sulfate A complex in plasma and kidney in terms of protein binding.
Zhang JS; Shen-Feng MA; Suenaga A; Otagiri M
Biol Pharm Bull; 2001 Aug; 24(8):970-2. PubMed ID: 11510498
[TBL] [Abstract][Full Text] [Related]
10. Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury.
Saleh S; Ain-Shoka AA; El-Demerdash E; Khalef MM
Chemotherapy; 2009; 55(6):399-406. PubMed ID: 19955745
[TBL] [Abstract][Full Text] [Related]
11. Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs.
Haschke M; Vitins T; Lüde S; Todesco L; Novakova K; Herrmann R; Krähenbühl S
Nephrol Dial Transplant; 2010 Feb; 25(2):426-33. PubMed ID: 19736245
[TBL] [Abstract][Full Text] [Related]
12. Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats.
Uehara T; Watanabe H; Itoh F; Inoue S; Koshida H; Nakamura M; Yamate J; Maruyama T
Arch Toxicol; 2005 Aug; 79(8):451-60. PubMed ID: 15856183
[TBL] [Abstract][Full Text] [Related]
13. Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity.
Nagai N; Hotta K; Yamamura H; Ogata H
Cancer Chemother Pharmacol; 1995; 36(5):404-10. PubMed ID: 7634382
[TBL] [Abstract][Full Text] [Related]
14. Scavenging activity of indole compounds against cisplatin-induced reactive oxygen species.
Fukutomi J; Fukuda A; Fukuda S; Hara M; Terada A; Yoshida M
Life Sci; 2006 Dec; 80(3):254-7. PubMed ID: 17049361
[TBL] [Abstract][Full Text] [Related]
15. Tubular dysfunction after peritonectomy and chemohyperthermic treatment with cisplatin.
La Manna G; Virzì S; Deraco M; Capelli I; Accorsi A; Dalmastri V; Comai G; Bonomi S; Grassi A; Selva S; Feliciangeli G; Scolari M; Stefoni S
In Vivo; 2006; 20(6A):703-6. PubMed ID: 17203749
[TBL] [Abstract][Full Text] [Related]
16. Lipid peroxides and antioxidant enzymes in cisplatin-induced chronic nephrotoxicity in rats.
González R; Romay C; Borrego A; Hernández F; Merino N; Zamora Z; Rojas E
Mediators Inflamm; 2005 Aug; 2005(3):139-43. PubMed ID: 16106099
[TBL] [Abstract][Full Text] [Related]
17. [Measurement of creatinine clearance and urinary NAG for the evaluation of cis-platinum induced nephrotoxicity].
Kubota A; Yoshida T; Tsukuda M; Furukawa S; Miyata K; Mochimatsu I; Sawaki S
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2599-605. PubMed ID: 2774590
[TBL] [Abstract][Full Text] [Related]
18. [Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study].
Vaira M; Barone R; Aghemo B; Mioli PR; De Simone M
Minerva Med; 2001 Aug; 92(4):207-11. PubMed ID: 11535965
[TBL] [Abstract][Full Text] [Related]
19. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat.
Yonezawa A; Masuda S; Nishihara K; Yano I; Katsura T; Inui K
Biochem Pharmacol; 2005 Dec; 70(12):1823-31. PubMed ID: 16242669
[TBL] [Abstract][Full Text] [Related]
20. [Clinical investigation of cis-platinum nephrotoxicity in 244 cases of primary lung cancer].
Soejima A; Inoue T; Suzuki M; Waku M; Nakabayashi K; Kitamoto K; Nagasawa T
Nihon Jinzo Gakkai Shi; 1992 Jul; 34(7):801-6. PubMed ID: 1479719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
